Neoadjuvant combo efficacious in high-risk prostate cancer

One-third of men with high-risk prostate cancer achieved pathologic complete response (pCR) or near-complete response to 6 months of preoperative therapy with abiraterone acetate (ZYTIGA), leuprolide, and prednisone, investigators reported at the American Society of Clinical Oncology annual meeting in Chicago.

Related Videos

Related Content

Advertisement

January 10th 2025

FDA clears chemiluminescence-based immunoassay for free testosterone

Hannah Clarke

The test can provide results in 48 minutes to provide diagnostic insights for conditions such as hypogonadism, impotence, polycystic ovarian syndrome, and other androgenital syndromes.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 10th 2025

FDA greenlights phase 2 SURF302 trial of TYRA-300 in NMIBC

Hannah Clarke

"We expect to initiate patient dosing in the second quarter of this year, with initial three-month [complete response] data to follow," says Doug Warner.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

January 8th 2025

Disitamab vedotin/toripalimab shows encouraging efficacy in urothelial carcinoma

Hannah Clarke

At a median follow-up of 33.2 months, the confirmed objective response rate was 73.2%.

Related Content

Advertisement

January 10th 2025

FDA clears chemiluminescence-based immunoassay for free testosterone

Hannah Clarke

The test can provide results in 48 minutes to provide diagnostic insights for conditions such as hypogonadism, impotence, polycystic ovarian syndrome, and other androgenital syndromes.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 10th 2025

FDA greenlights phase 2 SURF302 trial of TYRA-300 in NMIBC

Hannah Clarke

"We expect to initiate patient dosing in the second quarter of this year, with initial three-month [complete response] data to follow," says Doug Warner.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

January 8th 2025

Disitamab vedotin/toripalimab shows encouraging efficacy in urothelial carcinoma

Hannah Clarke

At a median follow-up of 33.2 months, the confirmed objective response rate was 73.2%.